Vanta Bioscience Profit & Loss Annual

BSE: 540729 | NSE: - | ISIN: INE695X01011 | Sector: Biotechnology & Drugs

47.32 +2.16 (4.78%)Updated : 26 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	9.72	6.28	9.69	10.04
Total Revenue	9.72	6.28	9.69	10.04
Costof Revenue Total	0.72	0.95	0.70	0.82
Gross Profit	9.00	5.33	8.99	9.22
Selling/ General/ Admin Expenses Total	3.79	3.94	3.09	5.22
Depreciation/ Amortization	4.50	2.67	1.32	1.25
Other Operating Expenses Total	3.90	3.78	2.43	-
Total Operating Expense	12.91	11.34	7.54	7.29
Operating Income	-3.18	-5.06	2.15	2.75
Interest Inc( Exp) Net- Non- Op Total	-57.49	-56.05	-23.47	-21.06
Other Net	0.11	0.41	0.42	-0.07
Net Income Before Taxes	-8.83	-10.26	0.23	0.59
Provisionfor Income Taxes	-0.22	0.18	0.14	0.14
Net Income After Taxes	-8.61	-10.44	0.09	0.45
Minority Interest	6.29	3.96	-	0.00
Net Income Before Extra Items	-2.32	-6.48	0.09	0.45
Net Income	-2.32	-6.48	0.09	0.45
Income Availableto Com Excl Extra Ord	-2.32	-6.48	0.09	0.45
Income Availableto Com Incl Extra Ord	-2.32	-6.48	0.09	0.45
Diluted Net Income	-2.32	-6.48	0.09	0.45
Diluted Weighted Average Shares	0.63	0.63	0.63	0.63
Diluted EPS Excluding Extra Ord Items	-3.67	-10.27	0.14	0.71
Diluted Normalized EPS	-3.67	-10.27	0.14	0.69
Total Adjustmentsto Net Income	-	0.00	-	-
Unusual Expense( Income)	-	-	-	0.00
Gain( Loss)on Saleof Assets	-	-	-	0.22